CEACAM5 and neoplasm: A pair combination of CEA-IL-2v and three human IgG1-isotype antibodies—trastuzumab, cetuximab, and imgatuzumab—demonstrates superior efficacy and anti-tumor effects compared to the monotherapies [47,69,70].